Arbutus Biopharma Corporation

ABUS · NASDAQ

ABUS is suddenly cash-relevant because of a Moderna/Genevant settlement receivable, but the core company is still a small clinical-stage HBV developer that must prove imdusiran can move beyond Phase 2a signals.

Follow Add to Watchlist Ask Question

NASDAQ ABUS Coverage Bootstrap Biotechnology Chronic Hepatitis B RNAi

Latest ReportMay 13, 2026Arbutus (ABUS): the $179M settlement windfall hiding inside a pre-commercial HBV biotechView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters1 of 1 reports match

Clear filters

Add tags

Selected tags

BiotechnologyRNAI

Clear tags

MatchAny tag All tags

Latest Thesis

Arbutus (ABUS): the $179M settlement windfall hiding inside a pre-commercial HBV biotech

May 13, 2026Research reportSlides available

Read report Open slides Discussion (0)

Arbutus Biopharma Corporation(ABUS): the $179M settlement windfall hiding inside a pre-commerMay 13, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 1 reports ->

ReportTypeUpdatedReadActions

Arbutus (ABUS): the $179M settlement windfall hiding inside a pre-commercial HBV biotechABUS is suddenly cash-relevant because of a Moderna/Genevant settlement receivable, but the core company is still a small clinical-stage HBV developer that must prove imdusiran can move beyond Phase 2a signals.NASDAQMay 13, 2026Research reportRead Slides